Constantinovici A, Cristescu A M
III-rd. Neurosurgical Department, Gh. Marinescu Hospital, Bucharest.
Zentralbl Neurochir. 1989;50(2):109-14.
This paper reports on the evaluation of 29 patients with I-st grade, 35 patients with II-nd grade astrocytomas and 145 patients with malignant astrocytomas (gr. III or IV) with a postoperative Karnofski index of minimum 60, treated with wide surgical resections, chemotherapy (CCNU 130 mg/m2 body surface) and irradiation with 60Co or conventional roentgen-therapy, in doses of 50-60 Gy, fractionated applied. The control group was formed by patients treated surgically and by postoperative irradiation: 5 with I-st and II-nd grade astrocytomas and 30 with malignant ones. Comparison of the results shows a median survival of 71.5 weeks for I-st grade, 66.5 weeks for II-nd grade and 44 weeks for high malignant astrocytomas treated only with CCNU, as against 150, 119 and respectively 73 weeks when chemotherapy was associated with irradiation with 60Co. The statistical differences between the results of radiochemotherapy and the cobalt-therapy applied alone were also very significant. The long-term survival: at 5 years for I-st and II-nd degree and at 1 and 3 year for malignant astrocytomas revealed the same superiority of the complex associated treatment (radio-chemo-surgical). No significant differences in survival were recorded in relation to age, sex and site in surgically treatable cases. However the infiltrative character of the tumors significantly aggravate the prognosis. It is concluded that association of chemotherapy with cobalt-therapy postoperatively brings about a statistical significant increase in survival as against postoperative chemotherapy or irradiation applied alone.
本文报告了对29例I级、35例II级星形细胞瘤患者以及145例恶性星形细胞瘤(III级或IV级)患者的评估结果。这些患者术后卡诺夫斯基指数最低为60,接受了广泛手术切除、化疗(环己亚硝脲130mg/m²体表面积)以及60钴或传统X线治疗,剂量为50 - 60Gy,分次应用。对照组由接受手术及术后放疗的患者组成:5例I级和II级星形细胞瘤患者以及30例恶性星形细胞瘤患者。结果比较显示,仅接受环己亚硝脲治疗的I级星形细胞瘤患者中位生存期为71.5周,II级为66.5周,高恶性星形细胞瘤为44周;而化疗联合60钴放疗时,相应的中位生存期分别为150周、119周和73周。放化疗结果与单独应用钴治疗结果之间的统计学差异也非常显著。长期生存率:I级和II级为5年,恶性星形细胞瘤为1年和3年,显示出综合联合治疗(放疗 - 化疗 - 手术)同样具有优势。在可手术治疗的病例中,年龄、性别和部位对生存率无显著差异。然而,肿瘤的浸润性特征显著恶化了预后。结论是,术后化疗联合钴治疗与单独应用术后化疗或放疗相比,能使生存率在统计学上显著提高。